Update on the ICARIA-MM trial

(7:58)

Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma

(1:3)

Results of the ASPIRE trial for MM: the addition of carfilzomib

(1:4)

IKEMA trial update: Isatuximab in MM

(2:10)

MM trial highlights from ASCO 2018

(2:34)

ICARIA-MM Phase III Trial Overview

(2:36)

The Benefits of Participating in a Myeloma Clinical Trial

(2:11)

Clinical translation of carfilzomib trial data for MM treatment

(1:45)

Omaha jury hears testimony from primary investigator in trial against surgeon accused of manslaug...

(2:34)

Mezigdomide Plus Dexamethasone in RRMM: CC-92480-MM-002 Trial Results| Paul Richardson, MD |ASH 2023

(2:47)

Switching IMiDs: The OPTIMISMM Trial’s Impact on MM

(3:59)

Phase 2 NFKB2 rearrangement-driven MM trial: predictor of sensitivity to PIs?

(1:39)

SWOG S0777 trial: lenalidomide, dexamethasone and bortezomib for the treatment of MM

(2:34)

Myeloma XI trial: impact of MRD on treatment response in MM

(1:19)

MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24

(2:4)

How can MM patients become involved in the clinical trial networks?

(54)

Primary and Secondary Endpoints in a Clinical Trial: What are they? #myeloma

(4:13)

Trial updates in R/R MM from ASCO: ARROW, MMY1001 \u0026 OPTIMISMM

(6:40)

ASCO 2019: Isatuximab ICARIA-MM Trial Updates with Dr. Paul Richardson

(5:11)

BelaRd trial: belamaf, lenalidomide, and dex in newly diagnosed MM

(1:7)